Download MediGene Adds Romania and Bulgaria to Existing

Press Release
MediGene Adds Romania and Bulgaria to Existing
Partnership Agreement with Meditrina for the
Commercialization of Veregen®
Martinsried/Munich, January 25, 2011. The biotech company MediGene AG (Frankfurt, Prime
Standard) announced today that its existing partnership with Meditrina Pharmaceuticals Ltd.,
Greece, for the commercialization of Veregen® Ointment has been expanded to include
Romania and Bulgaria. The previous agreement had been concluded for the commercialization
of Veregen® in Greece and Cyprus. According to the new agreement, Meditrina will (via its
subsidiary Solartium) promote and distribute the drug for the treatment of genital warts in both
Romania and Bulgaria. In sum, MediGene is entitled to successive payments of up to
EUR 1.2 million for the four countries (previously agreed: EUR 900,000), depending on the
achievement of set milestones. Furthermore, MediGene will supply Meditrina with drug product
and obtain royalties on the sales revenue generated with Veregen® in the form of a double-digit
percentage share.
MediGene has already entered into several marketing partnerships for Veregen®, for example
with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with
Laboratoires Expanscience for France, with Juste S.A.Q.F. for Spain and Portugal and with a
number of other partners across Europe and Asia. MediGene is planning to continue this global
licensing strategy.
Veregen® is currently available on the US, German, and Austrian markets. A second wave of
marketing applications within the European mutual recognition procedure is planned, with
Germany serving as the reference state in this process.
Veregen®: Veregen® (formerly Polyphenon E® Ointment) for the topical treatment of external
genital warts is a concentrate of catechins with a complex defined composition, extracted from
green tea leaves. MediGene acquired the basic rights to the active ingredient in Veregen® from
the Canadian company Epitome Pharmaceuticals, Inc. in 1999, and was solely responsible for
the drug’s successful preclinical and clinical development, as well as the approval process.
Moreover, the patent protection has been further upgraded by a number of proprietary
inventions. Sinecatechines 15 % ointment (Veregen®) is also now recommended as a treatment
option by the US Department of Health and Human Services Center for Disease Control and
Prevention in the Sexually Transmitted Diseases Treatment Guidelines 2010 for the treatment
of genital warts.
Meditrina: Meditrina Pharmaceuticals Ltd., founded in 2005, is a privately held, growing
pharmaceutical company which focuses on in-licensing, marketing, and sales of pharmaceutical
products. Among others, the company specializes in the fields of gynecology, dermatology, and
oncology. For further information about Meditrina please visit www.meditrina.gr.
Solartium: Solartium Group srl, established in 2007 by Italian investors, is headquartered in
Bucharest, Romania and is coordinating activities in Romania, Bulgaria and Moldova. In
January 2011, Meditrina became its major shareholder. Solartium is managed by local
professionals with proven skills and competences built in several years of experience in
multinational pharma companies. Solartium focuses on gynecology, dermatology and pediatrics.
For further information about Solartium please visit www.solartium.ro.
This press release contains forward-looking statements representing the opinion of MediGene as of the
date of this release. The actual results achieved by MediGene may differ significantly from the forwardlooking statements made herein. MediGene is not bound to update any of these forward-looking
®
®
®
statements. MediGene and Veregen are registered trademarks of MediGene AG. Polyphenon E is a
trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company
headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has several drug
candidates in clinical development and possesses innovative platform technologies. MediGene
focuses on clinical research and development of novel drugs with focus on oncology.
Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: ++49 - 89 - 85 65 - 3301
Fax: ++49 - 89 - 85 65 - 29 20
Email: [email protected]